Aromatase Inhibitors Reduce the Expression of a Hypoxia Metagene in Oestrogen Receptor Positive Breast Cancer in Postmenopausal Women.

被引：0
|
作者：
Ghazoui, Z.
Buffa, F. M.
Dunbier, A. K.
Anderson, H.
Dexter, T.
Smith, I. E.
Harris, A. L.
Dowsett, M.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Breakthrough Breast Canc Res Ctr, London, England
[3] John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：518S / 518S
页数：1
相关论文
共 50 条
  • [41] Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women
    Kao, YC
    Okubo, T
    Sun, XZ
    Chen, S
    ANTICANCER RESEARCH, 1999, 19 (3A) : 2049 - 2056
  • [42] Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor-Treated ER-Positive Breast Cancer
    Ghazoui, Zara
    Buffa, Francesca M.
    Dunbier, Anita K.
    Anderson, Helen
    Dexter, Tim
    Detre, Simone
    Salter, Janine
    Smith, Ian E.
    Harris, Adrian L.
    Dowsett, Mitchell
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 3005 - 3012
  • [43] Postmenopausal breast cancer, aromatase inhibitors, and bone health
    Heneghan, H. M.
    McKenna, M.
    Walshe, J.
    Rothwell, J.
    Evoy, D.
    Geraghty, J.
    McDermott, E.
    Prichard, R. S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : 416 - 417
  • [44] Low-penetrance susceptibility variants and postmenopausal oestrogen receptor positive breast cancer
    Ozgoz, Asuman
    Mutlu Icduygu, FadIme
    Yukselturk, Aysegul
    Samli, Hale
    HekImler ozturk, Kuyas
    Baskan, Zuhal
    JOURNAL OF GENETICS, 2020, 99 (01)
  • [45] Low-penetrance susceptibility variants and postmenopausal oestrogen receptor positive breast cancer
    Asuman Özgöz
    Fadİme Mutlu İçduygu
    Ayşegül Yükseltürk
    Hale ŞamlI
    Kuyaş Hekİmler Öztürk
    Zuhal Başkan
    Journal of Genetics, 2020, 99
  • [46] Aromatase Inhibitors for Adjuvant Treatment of Postmenopausal Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1366): : 47 - 48
  • [47] Risks and benefits of aromatase inhibitors in postmenopausal breast cancer
    Michaud, LB
    Buzdar, AU
    DRUG SAFETY, 1999, 21 (04) : 297 - 309
  • [48] Risks and Benefits of Aromatase Inhibitors in Postmenopausal Breast Cancer
    Laura Boehnke Michaud
    Aman U. Buzdar
    Drug Safety, 1999, 21 : 297 - 309
  • [49] Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
    Aapro, M.
    van de Velde, C. J. H.
    Markopoulos, C.
    Bartlett, J. M. S.
    Putter, H.
    Coleman, R. E.
    BREAST, 2013, 22 (04): : 488 - 494
  • [50] Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?
    Dhesy-Thind, Sukhbinder K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1408 - 1410
12345